BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Casi Pharmaceuticals, Inc. CASIF
6 fiscal years on record · USD · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 20.7M
Revenue, FY2025 · full 6-year series below
Revenue $M
Net income $M
FY2025 · Revenue 20.7 · Net income -48.1
20M40M-20M-40M
202020232025
Compound annual growth
Revenue compounded at +6.5% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−232 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -217.3% · Net -232.0%
-100%-200%-300%
202020222025
ROE
FY2024 · ROE -301.8%
-100%-200%-300%
202020222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on assets-121.2%
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| Income tax $B | ◌ | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.59 | −2.56 | −2.02 | −3.01 | −2.69 | −4.37 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — |
| ROE % | — | −301.8 | −78.4 | −63.6 | −44.2 | −59.2 |
| Shares out B | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 6 of the 6 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2020